title: Osteopontin is a useful predictor of bone metastasis and survival in patients with locally advanced nasopharyngeal carcinoma.
abstract: Bone is the most common metastatic site in nasopharyngeal carcinoma (NPC). Osteopontin (OPN) and bone sialoprotein (BSP) are demonstrated to be involved in multiple steps of distant metastasis and correlate with bone metastasis (BM) in cancers. We aim to explore the impacts of OPN and BSP on the prognosis of the patients with locally advanced NPC. A tissue microarray including 162 locally advanced NPC specimens was generated for immunohistochemical evaluation. All of the patients received curative treatment. Twenty-two patients developed BM during follow-up. The OPN expression level was higher in patients with BM than in those without BM (p = 0.005), whereas no significant difference of the BSP expression level was noted (p = 0.634). Univariate analysis demonstrated that a higher level of OPN expression associated with a poorer 8-year metastasis-free survival (MFS) rate (p < 0.001), 8-year bone metastasis-free survival (BMFS) rate (93.6 vs. 87.5 vs. 64.5% for immunoreactivity score 1, 2 and 3, respectively; p = 0.001) and median overall survival (OS) time (p < 0.001). Multivariate Cox analysis confirmed that high level of OPN expression was independent factor associated with decreased BMFS (p = 0.02), MFS (p < 0.001) and OS (p < 0.001). Our findings indicate that OPN is a prognostic biomarker for BM and survival in patients with locally advanced NPC, and therefore it is useful in identifying the patients with an increased risk of cancer progression and BM to guide tailored therapy.
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Xue
authors.initials: X
authors.lastname: Hou
authors.affiliation: Department of Oncology, Peking University Shenzhen Hospital, Shenzhen City, Guangdong Province, People's Republic of China.
authors.forename: Xuan
authors.initials: X
authors.lastname: Wu
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, People's Republic of China.|Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Peiyu
authors.initials: P
authors.lastname: Huang
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Jianhua
authors.initials: J
authors.lastname: Zhan
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Ting
authors.initials: T
authors.lastname: Zhou
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, People's Republic of China.|Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Yuxiang
authors.initials: Y
authors.lastname: Ma
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Tao
authors.initials: T
authors.lastname: Qin
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, People's Republic of China.|Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Rongzhen
authors.initials: R
authors.lastname: Luo
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, People's Republic of China.|Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Yanfen
authors.initials: Y
authors.lastname: Feng
authors.affiliation: Institute of Medical Statistics and Epidemiology, Sun Yat-sen University, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Likun
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou City, Guangdong Province, People's Republic of China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, People's Republic of China.
authors.forename: Li
authors.identifier: http://orcid.org/0000-0003-0595-0761
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism; D001859:Bone Neoplasms / Q000378:metabolism* / Q000556:secondary*; D002277:Carcinoma; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D058574:Integrin-Binding Sialoprotein / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism* / Q000473:pathology*; D053495:Osteopontin / Q000378:metabolism*; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D046888:Tissue Array Analysis; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D058574:Integrin-Binding Sialoprotein; D053495:Osteopontin
keywords: bone metastasis; bone sialoprotein; nasopharyngeal neoplasms; osteopontin; prognosis